Prognostic value of β1 integrin expression in metastatic melanoma

Melanoma Research

Volumn 10, Issue 3, 2000, Pages 243-251

  Vihinen, P ^a   Nikkola, J ^a   Vlaykova, T ^a   Hahka Kemppinen, M ^a   Talve, L ^a   Heino, J ^a   Pyrhonen, S ^a  

^a UNIVERSITY OF TURKU   (Finland)

Author keywords

Immunohistochemistry; Metastatic melanoma; Prognosis; 1 Integrin expression

Indexed keywords

ANTINEOPLASTIC AGENT; BETA1 INTEGRIN; TUMOR MARKER;

ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CELL FUNCTION; CLINICAL ARTICLE; CONTROLLED STUDY; GROWTH REGULATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALIGNANT TRANSFORMATION; MELANOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; STAINING; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR GROWTH; BIOPSY; BRAIN TUMOR; IMMUNOTHERAPY; LYMPH NODE; LYMPH NODE METASTASIS; METABOLISM; METASTASIS; MORTALITY; PATHOLOGY; PREOPERATIVE CARE; PROSPECTIVE STUDY; SKIN TUMOR; TIME;

ANTIGENS, CD29; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOPSY; BRAIN NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; LYMPH NODES; LYMPHATIC METASTASIS; MELANOMA; PREOPERATIVE CARE; PROGNOSIS; PROSPECTIVE STUDIES; SKIN NEOPLASMS; SURVIVAL RATE; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 0033623965     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-200006000-00006     Document Type: Article

References (40)

1. An analysis of prognostic factors in 8500 patients with cutaneous melanoma
2. Thickness cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma
3. Prognostic factors in 1,521 melanoma patients with distant metastases
4. Integrins: Versatility, modulation, and signalling in cell adhesion
5. Biology of tumour cell invasion: Interplay of cell adhesion and matrix degradation
6. Isolation, cloning, and sequence analysis of the integrin subunit α10, a β1-associated collagen binding integrin expressed on chondrocytes
7. Integrins and signal transduction pathways: The road taken
8. Regulation of cell adhesion receptors by transforming growth factor-β. Concomitant regulation of integrins that share a common β1 subunit
9. Regulation of integrin-type cell adhesion receptors by cytokines
10. Identification of a melanoma progression antigen as an integrin VLA-2
11. Cell adhesion receptor expression during melanoma progression and metastasis
12. Expression of the integrin α4β1 on melanoma cells can inhibit the invasive stage of metastasis formation
13. Tumour progression in human malignant melanoma is associated with changes in α6/β1 laminin receptor
14. Suppression of mouse melanoma metastasis by EA-1, a monoclonal antibody specific for α6 integrins
15. Integrin αvβ3 antagonists promote tumour regression by inducing apoptosis of angiogenic blood vessels
16. A promising interferon plus four-drug chemotherapy regimen for metastatic melanoma
17. Glycoproteins of 210,000 and 130,000 m.w. on activated T cells: Cell distribution and antigenic relation to components on resting cells and T cell lines
18. Use of the monoclonal antibody 12F1 to characterise the differentiation antigen VLA-2
19. Identification and characterisation of a novel antigen complex on mouse mammary tumour cells using a monoclonal antibody against platelet glycoprotein Ic
20. Integrins αvβ3 and αvβ5 contribute to cell attachment to vitronectin but differentially distribute on the cell surface
21. Expression of integrins and basement membrane components by wound keratinocytes
22. The prognosis of patients with stage III melanoma. Prospective long-term study of 286 patients of the Fachklinik Hornheide
23. The prognostic significance of tumour vascularity in intermediate-thickness (0.76-4.0 mm thick) skin melanoma. A quantitative histologic study
24. Flow cytofluorometric DNA analyses of metastases of human malignant melanomas
25. Correlation of DNA ploidy and S-phase fraction with chemotherapeutic response and survival in a randomised study of disseminated malignant melanoma
26. Prognostic factors in patients with metastatic malignant melanoma. A multivariate analysis
27. Clinical relevance of ICAM-1 expression in primary lesions and serum of patients with malignant melanoma
28. Serum interleukin 6 and C-reactive protein levels correlate with resistance to IL-2 therapy and poor survival in melanoma patients
29. Elevated serum levels of S100 and survival in metastatic malignant melanoma
30. Beta 1 integrin expression in malignant melanoma predicts occult lymph node metastases
31. β3 Integrin expression in melanoma predicts subsequent metastasis
32. Association with clinical outcome of expression of VLA-4 in primary cutaneous malignant melanoma as well as P-selectin and E-selectin on intratumoral vessels
33. Favourable melanoma prognosis associated with the expression of the tumour necrosis factor receptor and the α1β1 integrin: A preliminary report
34. Loss of expression of transforming growth factor type I and type II receptors correlates with tumour grade in human prostate cancer tissues
35. Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability
36. Integrin α5β1 expression negatively regulates cell growth: Reversal by attachment to fibronectin
37. Interferon-alpha restores normal beta 1 integrin-mediated inhibition of hematopoietic progenitor proliferation by the marrow in chronic myelogenous leukemia
38. Loss of adhesion to basement membrane components but not to keratinocytes in proliferating melanocytes
39. Prognostic value of biomarkers in malignant melanoma
40. In vitro modulation of tumour progression-associated properties of hormone refractory prostate carcinoma cell lines by cytokines